TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 12819517
Drug: Therapeutic drug
Normalized name: Moisturel Therapeutic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Therapeutic drug monitoring (TDM) for nelfinavir
Study: 12819517
Drug: Therapeutic drug
Normalized name: Moisturel Therapeutic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Therapeutic drug monitoring (TDM) for indinavir
Study: 12819517
Drug: Therapeutic drug
Normalized name: Moisturel Therapeutic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Therapeutic drug monitoring (TDM) for both drugs
Study: 12819517
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (no TDM) for both drugs
Study: 10099058
Drug: Montelukast 10
Normalized name: montelukast 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Montelukast 10 mg once daily (clinical dosage)
Study: 10099058
Drug: Montelukast 600
Approvals — FDA: no, EMA: no, PMDA: no
Description: Montelukast 600 mg (200 mg three times daily)
Study: 28118425
Drug: Lidocaine injections
Normalized name: Lidocaine
DrugBank: Lidocaine (DB00281)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Lidocaine injections
Study: 25088520
Drug: combined treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: combined treatment
Study: 17117182
Drug: Quadrivalent HPV
Normalized name: HPV, quadrivalent
Approvals — FDA: no, EMA: no, PMDA: no
Description: Quadrivalent HPV 6/11/16/18 L1 virus-like particle vaccine
Study: 16929590
Drug: Silybum marianum
Normalized name: Silybum marianum
Approvals — FDA: no, EMA: no, PMDA: no
Description: Silybum marianum 160 mg orally three times a week for four weeks
Study: 28589965
Drug: No-treatment (control)
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: No-treatment (control)
Study: 11336929
Drug: Verteporfin therapy
Normalized name: Verteporfin
DrugBank: Verteporfin (DB00460)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Verteporfin therapy (6 mg per square meter of body surface area) administered by intravenous infusion over 10 minutes, followed by laser treatment at 689 nm.
Study: 11336929
Drug: Placebo therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo therapy (5% dextrose in water) administered by intravenous infusion over 10 minutes, followed by sham laser treatment.
Study: 3304409
Drug: Routine postoperative
Normalized name: povidone-iodine
DrugBank: Povidone-iodine (DB06812)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Routine postoperative therapy alone
Study: 31486230
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of canagliflozin (100 mg/d) and teneligliptin (20 mg/d)
Study: 31486230
Drug: SGLT2 inhibitor
Normalized name: Fibrinolysis inhibitor
DrugBank: Aprotinin (DB06692)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: SGLT2 inhibitor monotherapy (canagliflozin 100 mg/d)
Study: 31198139
Drug: CPIS-guided therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: CPIS-guided therapy
Study: 26686794
Drug: Cinacalcet in
Normalized name: Product containing cinacalcet in oral dose form (medicinal product form)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cinacalcet in addition to conventional therapy
Study: 19542983
Drug: Pregabalin 150
Normalized name: pregabalin 150 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pregabalin 150 mg/day
Study: 8325041
Drug: Rifaximin (1200
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rifaximin (1200 mg/day for 15 days)
Study: 8325041
Drug: Lactulose (30
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lactulose (30 g/day for 15 days)
Study: 3090597
Drug: 0.347 g/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.347 g/kg ethanol
Study: 3090597
Drug: 0.694 g/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.694 g/kg ethanol
Study: 29226494
Drug: Cognitive-behavioural therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cognitive-behavioural therapy (CBT) for problem gambling
Study: 29226494
Drug: Routine CBT
Approvals — FDA: no, EMA: no, PMDA: no
Description: Routine CBT treatments
Study: 29226494
Drug: Exposure therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Exposure therapy for problem gambling
Study: 11414348
Drug: Treatment for
Normalized name: Hair Regrowth Treatment For Men
DrugBank: Minoxidil (DB00350)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Treatment for alcohol and drug abuse
Study: 7826557
Drug: Low-sodium/high-potassium diet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low-sodium/high-potassium diet with chlorthalidone (25 mg/day)
Study: 7826557
Drug: Low-sodium/high-potassium diet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low-sodium/high-potassium diet with atenolol (50 mg/day)
Study: 7826557
Drug: Usual diet
Normalized name: phentermine hydrochloride Oral Capsule [T-Diet]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Usual diet with chlorthalidone (25 mg/day)
Study: 7826557
Drug: Usual diet
Normalized name: phentermine hydrochloride Oral Capsule [T-Diet]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Usual diet with atenolol (50 mg/day)
Study: 3279101
Drug: Intravenous nutrient
Normalized name: Votrient
DrugBank: Pazopanib (DB06589)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Intravenous nutrient infusion containing amino acids (3.4 g/h), dextrose (20 g/h), and insulin (1.6 units/h)
Study: 3279101
Drug: Intravenous nutrient
Normalized name: Votrient
DrugBank: Pazopanib (DB06589)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Intravenous nutrient infusion containing amino acids, glucose, and insulin
Study: 22891287
Drug: Intramuscular route
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intramuscular route of subvirion inactivated influenza A virus subtype H5N1 vaccine (38.7 μg of H5N1 hemagglutinin)
Study: 22891287
Drug: Intradermal route
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intradermal route of subvirion inactivated influenza A virus subtype H5N1 vaccine (38.7 μg of H5N1 hemagglutinin)
Study: 17483649
Drug: Oral risedronate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral risedronate 5 mg/day after the fifth postoperative day
Study: 10475183
Drug: Daily application
Approvals — FDA: no, EMA: no, PMDA: no
Description: Daily application of a sun protection factor 15-plus sunscreen
Study: 10475183
Drug: Betacarotene supplementation
Normalized name: betacarotene
DrugBank: Beta carotene (DB06755)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Betacarotene supplementation (30 mg per day)
Study: 10475183
Drug: Sunscreen plus
Normalized name: Sunmark Sunscreen Plus E and Aloe SPF 30
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sunscreen plus placebo tablets
Study: 25830400
Drug: Implant-supported fixed
Normalized name: Humalog Mix
Approvals — FDA: no, EMA: no, PMDA: no
Description: Implant-supported fixed partial dentures (IFPDs)
Study: 22057411
Drug: Acupuncture treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acupuncture treatment based on identified CM patterns
Study: 18723297
Drug: Dose-escalated three-dimensional
Normalized name: three-lobe sage extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dose-escalated three-dimensional conformal radiotherapy (3D-CRT) at doses of 66, 72, 78, and 84 Gy with concurrent Carmustine 80 mg/m² during RT and every 8 weeks for 6 cycles
Study: 17327934
Drug: Lansoprazole 60
Normalized name: dexlansoprazole 60 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lansoprazole 60 mg
Study: 7220406
Drug: Erythromycin estolate
Normalized name: Erythromycin Estolate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Erythromycin estolate preparation (500 mg)
Study: 7220406
Drug: Erythromycin propionate
Normalized name: erythromycin propionate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Erythromycin propionate preparation (500 mg)
Study: 7220406
Drug: Erythromycin stearate
Normalized name: Erythromycin Stearate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Erythromycin stearate preparation (500 mg)
Study: 23065731
Drug: Referral strategy
Normalized name: teferrol
DrugBank: Iron polymaltose (DB15763)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Referral strategy 2 (two of the following: IBP, HLA‐B27, sacroiliitis, family history of axial SpA, good response to non‐steroidal anti‐inflammatory drugs, extra‐articular manifestations)
Study: 10879638
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of fortified tobramycin (1.5%) and cefazolin (5%) solutions
Study: 27038225
Drug: p-synephrine (3
Approvals — FDA: no, EMA: no, PMDA: no
Description: p-synephrine (3 mg kg(-1))
Study: 22770575
Drug: Brinzolamide 1%
Normalized name: BRINZOLAMIDE 1% SUSP,OPH
Approvals — FDA: no, EMA: no, PMDA: no
Description: Brinzolamide 1% plus timolol 0.5% suspension
Study: 22770575
Drug: Dorzolamide 2%
Normalized name: Brimonidine Tartrate 0.1%, Dorzolamide 2% Ophthalmic drops, solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dorzolamide 2% plus timolol 0.5% solution
Study: 17261962
Drug: CPB with
Normalized name: Primatene with ephedrine Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: CPB with Baxter Duraflo II heparin-coated circuits, high doses of aprotinin, and pre-CPB hemofiltration
Study: 9553234
Drug: PCA buprenorphine
Normalized name: lauryl PCA
Approvals — FDA: no, EMA: no, PMDA: no
Description: PCA buprenorphine (intravenous)
Study: 8094940
Drug: Meperidine 50-100
Normalized name: meperidine 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Meperidine 50-100 mg + midazolam 1-3 mg
Study: 8094940
Drug: Fentanyl 50-100
Normalized name: fentanyl
DrugBank: Fentanyl (DB00813)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Fentanyl 50-100 micrograms + midazolam 1-3 mg
Study: 8094940
Drug: Sufentanil 5-10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sufentanil 5-10 micrograms + midazolam 1-3 mg
Study: 8094940
Drug: Alfentanil 150-300
Approvals — FDA: no, EMA: no, PMDA: no
Description: Alfentanil 150-300 micrograms + midazolam 1-3 mg
Study: 8094940
Drug: Meperidine 50-100
Normalized name: meperidine 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Meperidine 50-100 mg + midazolam 1-3 mg (lower gastrointestinal patients)
Study: 3775255
Drug: Omeprazole, buffered
Approvals — FDA: no, EMA: no, PMDA: no
Description: Omeprazole, buffered solution, doses of 10-60 mg
Study: 3775255
Drug: Omeprazole, buffered
Approvals — FDA: no, EMA: no, PMDA: no
Description: Omeprazole, buffered solution
Study: 31552510
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group - recreational activities twice a week for 16 weeks
Study: 30554821
Drug: Control: NT
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control: NT (no treatment)
Study: 28606970
Drug: Tight Control
Normalized name: kaolin light
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tight Control (TC; 4 weekly review with therapy escalation if criteria not met)
Study: 28606970
Drug: Standard Care
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard Care (SC; 12 weekly review)
Study: 25051297
Drug: Exposure treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Exposure treatment at 08.00 a.m. (high cortisol group)
Study: 25051297
Drug: Exposure treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Exposure treatment at 06.00 p.m. (low cortisol group)
Study: 18667099
Drug: Cognitive behaviour
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cognitive behaviour therapy (CBT) plus treatment as usual (TAU)
Study: 17315156
Drug: Intensive chemotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intensive chemotherapy (Group A)
Study: 17315156
Drug: Intensive chemotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intensive chemotherapy (Group B)
Study: 9673472
Drug: 0.5% betaxolol
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.5% betaxolol HCI, twice-daily bilateral topical ocular dosing for one year
Study: 2454788
Drug: Stimulants (vanillin,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Stimulants (vanillin, phenylethyl alcohol, limonene, menthol, anethol, benzaldehyde, carbon dioxide, mixture of vanillin and carbon dioxide)
Study: 27255289
Drug: S-1 25
Approvals — FDA: no, EMA: no, PMDA: no
Description: S-1 25 mg/m2 twice daily (cohort 3)
Study: 27255289
Drug: S-1 20
Approvals — FDA: no, EMA: no, PMDA: no
Description: S-1 20 mg/m2 twice daily (cohort 2)
Study: 26095389
Drug: Oesophagectomy plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oesophagectomy plus postoperative chemotherapy (92-POST)
Study: 26095389
Drug: Postoperative chemotherapy
Normalized name: menthol
DrugBank: Menthol (DB14123)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Postoperative chemotherapy (99-POST)
Study: 26095389
Drug: Preoperative chemotherapy
Normalized name: povidone-iodine
DrugBank: Povidone-iodine (DB06812)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Preoperative chemotherapy (99-PRE)
Study: 21788033
Drug: Degarelix 240/80
Approvals — FDA: no, EMA: no, PMDA: no
Description: Degarelix 240/80 mg
Study: 23258223
Drug: Goserelin 3.6
Normalized name: goserelin 3.6 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Goserelin 3.6 mg + bicalutamide flare protection (G+B)
Study: 21329822
Drug: 0.2% CTR
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.2% CTR solution alone
Study: 21329822
Drug: Combinations with
Normalized name: bucetin, combinations with psycholeptics
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combinations with 2% CHX or 0.2% CTR as final irrigating solution
Study: 19592625
Drug: Albiglutide 50
Normalized name: ALBIGLUTIDE 50MG/0.5ML INJ PEN 0.5ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: Albiglutide 50 mg biweekly
Study: 19592625
Drug: Albiglutide 100
Normalized name: albiglutide 100 MG/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: Albiglutide 100 mg monthly
Study: 16105862
Drug: L-Arg infusion
Normalized name: L-Arg
DrugBank: Arginine (DB00125)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: L-Arg infusion (30 g at 0.5 g/min)
Study: 16105862
Drug: L-Arg infusion
Normalized name: L-Arg
DrugBank: Arginine (DB00125)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: L-Arg infusion
Study: 15590800
Drug: Regimen A
Normalized name: CHLOROXYLENOL 5 g in 1000 mL TOPICAL SOAP [REGIMEN ANTIMICROBIAL]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Regimen A (short-acting morphine tablets and indomethacin rectal suppositories)
Study: 15590800
Drug: Regimen B
Normalized name: Anacin Aspirin Regimen Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Regimen B (long-acting morphine tablets for baseline pain, short-acting morphine tablets for breakthrough pain, and naproxen rectal suppositories)
Study: 3229870
Drug: Nilvadipine 16
Normalized name: nilvadipine 16 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nilvadipine 16 mg
Study: 3941792
Drug: gamma‐vinyl GABA
Approvals — FDA: no, EMA: no, PMDA: no
Description: gamma‐vinyl GABA therapy, 2 g daily for 2 weeks
Study: 28544762
Drug: tooth/tongue gel,
Approvals — FDA: no, EMA: no, PMDA: no
Description: tooth/tongue gel, tongue cleaner, and mouthwash containing amine fluoride/stannous fluoride and zinc lactate
Study: 22430344
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (no treatment for 2 months)
Study: 22430344
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (no treatment for 2 months after crossover)
Study: 22430344
Drug: Group 1
Normalized name: Chlamydophila psittaci biogroup 1 Ab
Approvals — FDA: no, EMA: no, PMDA: no
Description: Group 1 during treatment vs nontreatment
Study: 22430344
Drug: Group 2
Normalized name: Chlamydophila psittaci biogroup 2 Ab
Approvals — FDA: no, EMA: no, PMDA: no
Description: Group 2 during treatment vs nontreatment
Study: 20686751
Drug: Moderate dose
Approvals — FDA: no, EMA: no, PMDA: no
Description: Moderate dose of alcohol (0.65 g/kg) administered twice on separate days
Study: 12535286
Drug: Lipid-rich cream
Normalized name: guggul lipids
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lipid-rich cream
Study: 1896198
Drug: ATS injection,
Approvals — FDA: no, EMA: no, PMDA: no
Description: ATS injection, oral metronidazole, amoxycillin, diazepam suppositoria plus pyridoxin injection 100 mg on the first day followed by 25 mg orally on the next days
Study: 1896198
Drug: ATS injection,
Approvals — FDA: no, EMA: no, PMDA: no
Description: ATS injection, oral metronidazole, amoxycillin, diazepam suppositoria
Study: 6750396
Drug: Protriptyline treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Protriptyline treatment for 2 weeks
Study: 6750396
Drug: Protriptyline treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Protriptyline treatment for 6 months
Study: 30685099
Drug: LDL-C (per
Approvals — FDA: no, EMA: no, PMDA: no
Description: LDL-C (per 1 mg/dl increase)
Study: 23438224
Drug: Caffeine (1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Caffeine (1 mg·kg(‐1) BW)
Study: 23438224
Drug: Caffeine (3
Approvals — FDA: no, EMA: no, PMDA: no
Description: Caffeine (3 mg·kg(‐1) BW)
Study: 23438224
Drug: Caffeine (5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Caffeine (5 mg·kg(‐1) BW)
Study: 21953854
Drug: Venlafaxine hydrochloride
Normalized name: Venlafaxine Hydrochloride
DrugBank: Venlafaxine (DB00285)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Venlafaxine hydrochloride 150 mg modified release capsules of Ranbaxy
Study: 21953854
Drug: EFEXOR®-XR 150
Approvals — FDA: no, EMA: no, PMDA: no
Description: EFEXOR®-XR 150 mg capsules of Wyeth
Study: 19052813
Drug: Escin 5
Normalized name: Escin
DrugBank: Escin (DB15907)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Escin 5 mg
Study: 19052813
Drug: Escin 15
Normalized name: Escin
DrugBank: Escin (DB15907)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Escin 15 mg
Study: 19052813
Drug: Escin 25
Normalized name: beta-escin 250 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Escin 25 mg
Study: 17413838
Drug: Menopause Symptoms
Normalized name: Pamprin Multi-Symptom
Approvals — FDA: no, EMA: no, PMDA: no
Description: Menopause Symptoms Treatment Satisfaction Questionnaire (MS-TSQ)
Study: 15557412
Drug: Antioxidant vitamins
Normalized name: antioxidant vitamins with minerals
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antioxidant vitamins and minerals supplementation (120 mg of ascorbic acid, 30 mg of vitamin E, 6 mg of beta carotene, 100 µg of selenium, and 20 mg of zinc)
Study: 9836544
Drug: Adjuvant autolymphocyte
Normalized name: antilymphocyte immunoglobulin
DrugBank: Antilymphocyte immunoglobulin (horse) (DB09312)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Adjuvant autolymphocyte therapy (ALT) after radical nephrectomy
Study: 7858555
Drug: enalapril (mean
Approvals — FDA: no, EMA: no, PMDA: no
Description: enalapril (mean dose 19mg/day)
Study: 7858555
Drug: doxazosin (mean
Approvals — FDA: no, EMA: no, PMDA: no
Description: doxazosin (mean dose 5.2mg/day)
Study: 2551121
Drug: Vitamin D2
Normalized name: vitamin D2
DrugBank: Ergocalciferol (DB00153)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Vitamin D2 4000 IU daily for 24 weeks
Study: 2551121
Drug: Vitamin D3
Normalized name: Vitamin D3
DrugBank: Cholecalciferol (DB00169)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vitamin D3 4000 IU daily for 24 weeks
Study: 7198366
Drug: Metoprolol 0.22
Approvals — FDA: no, EMA: no, PMDA: no
Description: Metoprolol 0.22 mg mounted on ophthalmic rods
Study: 29557078
Drug: Mazindol 1-3
Normalized name: mazindol 1 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mazindol 1-3 mg/day
Study: 10699107
Drug: Dexamethasone (0.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dexamethasone (0.5 mg/kg birth weight at 12-18 hours of age and a second dose 12 hours later)
Study: 8222190
Drug: FUT‐175 (40
Approvals — FDA: no, EMA: no, PMDA: no
Description: FUT‐175 (40 mg/h during cardiopulmonary bypass)
Study: 8222190
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (only heparin)
Study: 25577300
Drug: Resveratrol (150
Approvals — FDA: no, EMA: no, PMDA: no
Description: Resveratrol (150 mg capsules, twice daily for three months)
Study: 24252844
Drug: Pioglitazone 45
Normalized name: pioglitazone 45 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pioglitazone 45 mg daily
Study: 21325137
Drug: Atorvastatin (80
Approvals — FDA: no, EMA: no, PMDA: no
Description: Atorvastatin (80 mg daily for 8 weeks)
Study: 19363221
Drug: Plerixafor with
Normalized name: Plerixafor
DrugBank: Plerixafor (DB06809)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Plerixafor with G-CSF
Study: 19363221
Drug: Placebo with
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo with G-CSF
Study: 17531579
Drug: Trandolapril add-on
Normalized name: Trandolapril
DrugBank: Trandolapril (DB00519)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Trandolapril add-on therapy
Study: 11568544
Drug: Dextromethorphan pediatric
Normalized name: dextromethorphan hydrobromide Oral Solution [Tussin Pediatric]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dextromethorphan pediatric cough syrup (1 mg/kg)
Study: 7696449
Drug: Pancrease (4
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pancrease (4 capsules t.d.s.)
Study: 7696449
Drug: Pancrease-HL (1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pancrease-HL (1 capsule t.d.s.)
Study: 3673204
Drug: Yeast-derived hepatitis
Normalized name: YEAST CELL,LIVE DERIVATIVE
Approvals — FDA: no, EMA: no, PMDA: no
Description: Yeast-derived hepatitis B vaccine (YDV)
Study: 3673204
Drug: Commercial plasma-derived
Normalized name: Haptoglobulin 1/1 (Plasma Derived)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Commercial plasma-derived vaccine (PDV)
Study: 25858203
Drug: Group therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Group therapy for 8 weeks
Study: 25858203
Drug: Group therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Group therapy utilizing positive psychology strategies
Study: 23075433
Drug: Diode laser
Approvals — FDA: no, EMA: no, PMDA: no
Description: Diode laser therapy adjunct to scaling and root planing (SRP)
Study: 17959037
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of celecoxib and octreotide
Study: 15050264
Drug: Silicone IOL
Approvals — FDA: no, EMA: no, PMDA: no
Description: Silicone IOL (Pharmacia CeeOn 911A) with polished capsule
Study: 15050264
Drug: Silicone IOL
Approvals — FDA: no, EMA: no, PMDA: no
Description: Silicone IOL (Pharmacia CeeOn 911A) with unpolished capsule
Study: 11329494
Drug: EtOH 0.8
Approvals — FDA: no, EMA: no, PMDA: no
Description: EtOH 0.8 g/kg
Study: 11329494
Drug: AMP 20
Normalized name: ROPIVACAINE HCL 1% INJ AMP 20ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: AMP 20 mg
Study: 11329494
Drug: AMP 10
Normalized name: ROPIVACAINE HCL 0.2% INJ AMP 10ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: AMP 10 mg
Study: 11329494
Drug: EtOH 0.8
Approvals — FDA: no, EMA: no, PMDA: no
Description: EtOH 0.8 g/kg and AMP 20 mg